Silver Book

Silver Book Fact

Catheter ablation reduces risk of stroke and death among AFib patients

Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from stroke versus 23.5% of those on medications alone.

Day, JD, BG Crandall, JS Osborn, JP Weiss, DL Lappe, T Bair, H May, JL Anderson, B Muhlestein, J Nelson, and TJ Bunch. Atrial Fibrillation Ablation Significantly Reduces Long-Term Mortality and Strokes in a Large Patient Population; 2010

Reference

Title
Atrial Fibrillation Ablation Significantly Reduces Long-Term Mortality and Strokes in a Large Patient Population
Publication
Heart Rhythm Society 2010 Scientific Sessions
Publication Date
2010
Authors
Day, JD, BG Crandall, JS Osborn, JP Weiss, DL Lappe, T Bair, H May, JL Anderson, B Muhlestein, J Nelson, and TJ Bunch

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
  • Per-patient annual cost of treating stroke in atrial fibrillation patients
    The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.